$10.11 $0.38 (3.9%)

04:00 PM EDT on 10/15/19

Cellectis (NASDAQ:CLLS)

CAPS Rating: 5 out of 5

Current Price $10.11 Mkt Cap $770.5M
Open $9.83 P/E Ratio 0.00
Prev. Close $9.73 Div. (Yield) $0.00 (0.0%)
Daily Range $9.73 - $10.34 Volume 87,754
52-Wk Range $9.50 - $20.84 Avg. Daily Vol.

Caps

How do you think NASDAQ:CLLS will perform against the market?

Add Stock to CAPS Watchlist

All Players

47 Outperform
0 Underperform
 

All-Star Players

20 Outperform
0 Underperform
 

Wall Street

1 Outperform
0 Underperform
 

Top NASDAQ:CLLS Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

zzlangerhans (99.81)
Submitted March 28, 2015

Cellectis is new to the Nasdaq and CAPS but it's an old friend to zzporte. Portefeuille originally began buying the stock below 5 in February 2014 and our gains on the stock since then are close to $50000. Portefeuille has a talent for spotting… More

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

NASDAQ:CLLS VS S&P 500 (SPY)

NASDAQ:CLLS Summary

Fools bullish on NASDAQ:CLLS are also bullish on:

Recent Community Commentary

Read the most recent pitches from players about CLLS.

Recs

0
Member Avatar shanelofgren (31.35) Submitted: 1/2/2019 1:01:17 PM : Outperform Start Price: $17.02 NASDAQ:CLLS Score: -59.98

Renewing pick: bet on allogeneic CAR-T, specifically their partnership with Allogen and their IP portfolio of technologies to KO the TRAC, B2M, and other key genes for allogeneic T cells. Some concerns about the quality of their clinical results suggesting that allogeneic CAR-T may be less efficacious, but upside in reduced time to dose, lot consistency, potential for repeat dosing, etc. I believe offer a higher clinical ceiling once optimal protocol (ie, always inclusion of anti CD52) is determined.

Recs

3
Member Avatar zzlangerhans (99.81) Submitted: 3/28/2015 4:23:27 AM : Outperform Start Price: $36.00 NASDAQ:CLLS Score: -117.30

Cellectis is new to the Nasdaq and CAPS but it's an old friend to zzporte. Portefeuille originally began buying the stock below 5 in February 2014 and our gains on the stock since then are close to $50000. Portefeuille has a talent for spotting European stocks in hot sectors before the rest of the market catches on and bids them up. In the case of Cellectis it's CAR-T. The potential advantage of Cellectis is that they are generating an allogeneic product that could be marketed "off-the-shelf" unlike the autologous therapeis being developed by Juno and Kite in the US. Cellectis hasn't even filed an IND for any of their CAR-T therapeutics so naturally they fall well into the speculative range of the biotech spectrum. Nevertheless, it's the hottest area in biotech right now so expect a lot of buoyancy in the segment until we see the first major setback or trial failure. We've built up quite a cushion of profits trading Cellectis so I imagine we'll continue to try and milk this cow a while longer.

Leaderboard

Find the members with the highest scoring picks in CLLS.

Score Leader

allforone

allforone (24.81) Score: +39.40

The Score Leader is the player with the highest score across all their picks in CLLS.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
NextGenStock < 20 9/11/2019 Outperform 5Y $12.41 -18.53% -0.28% -18.25 0 Comment
DeathStock 52.79 1/28/2019 Outperform 5Y $15.95 -36.61% +13.70% -50.31 0 Comment
gunda7907 < 20 1/17/2019 Outperform 5Y $16.90 -40.16% +14.29% -54.45 0 Comment
shanelofgren 31.35 1/2/2019 Outperform 5Y $17.02 -40.58% +19.39% -59.98 1 Comment
Reallynow222 97.48 11/19/2018 Outperform 5Y $21.63 -53.26% +9.87% -63.13 0 Comment
adasand 48.64 7/18/2018 Outperform 5Y $30.57 -66.93% +6.55% -73.48 0 Comment
jack0071 69.51 11/27/2017 Outperform 5Y $24.80 -59.23% +14.84% -74.07 0 Comment
portefeuille7 91.37 5/21/2018 Outperform 5Y $29.50 -65.73% +9.50% -75.23 0 Comment
portefeuille9 93.81 5/21/2018 Outperform 5Y $29.50 -65.73% +9.50% -75.23 0 Comment
portefeuille10 97.51 5/21/2018 Outperform 5Y $29.50 -65.73% +9.50% -75.23 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackJimCramer 86.41 12/22/2015 Outperform 3W $29.05 -65.20% +46.90% -112.10 0 Comment